On July 29, 2022 AimedBio and GC cell reported to have signed a co-development agreement for a CAR-NK cell therapy drug.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The contract aims to derive candidates for CAR-NK drugs using AimedBio’s ‘AMB015’ antibodies that bind to cancer-specific proteins.

Through this collaboration, AimedBio hopes to expand their antibody-based therapeutics development area from ADCs to cell therapy.

(Press release, AimedBio, JUL 29, 2022, View Source;s_keyword=&s_where=&start=20 [SID1234656923])